Efficacy of cryobiopsy during medical thoracoscopy for diagnosing malignant pleural mesothelioma

Lung, Respiratory and Thoracic Cancer

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment

JTO Clin Res Rep

Schmid S, Holer L, Gysel K, Koster KL, Rothschild SI, Boos LA, Frehner L, Cardoso Almeida S, Britschgi C, Metaxas Y, Mark M, Froesch P, Janthur WD, Allemann A, Waibel C, Von der Mühll-Schill C, Früh M, Mauti LA

doi: 10.1016/j.jtocrr.2024.100735

Lung, Respiratory and Thoracic Cancer

The IASLC Pleural Mesothelioma Staging Project: Proposal for Revision of the TNM Stage Groupings in the Forthcoming (Ninth) Edition of the TNM Classification for Pleural Mesothelioma

J Thorac Oncol

Nowak AK, Giroux DJ, Eisele M, Rosenthal A, Bille A, Gill RR, Kindler HL, Pass HI, Rice D, Ripley RT, Wolf A, Friedberg J, Nishimura K, Rusch VW, Members of the Staging and Prognostic Factors Committee, of the Advisory Boards and Participating Institutions

doi: 10.1016/j.jtho.2024.05.002

Lung, Respiratory and Thoracic Cancer

Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trial

Lung Cancer

Bylicki O, Guisier F, Scherpereel A, Daniel C, Swalduz A, Grolleau E, Bernardi M, Hominal S, Prevost JB, Pamart G, Marques MH, Cloarec N, Deshayes S, Raimbourg J, Veillon R, Oulkhouir Y, Audigier Valette C, Subtil F, Chouaïd C, Greillier L, GFPC

doi: 10.1016/j.lungcan.2024.107866

Lung, Respiratory and Thoracic Cancer

Treatment of Pleural Mesothelioma: ASCO Guideline Update

J Clin Oncol

Kindler HL, Ismaila N, Bazhenova L, Chu Q, Churpek JE, Dagogo-Jack I, Bryan DS, Drazer MW, Forde P, Husain AN, Sauter JL, Rusch V, Bradbury PA, Cho BCJ, de Perrot M, Ghafoor A, Graham DL, Khorshid O, Lebensohn A, White J, Hassan R

doi: 10.1200/JCO-24-02425

Multiple Myeloma (MM)

Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed multiple myeloma: A systematic review and meta-analysis

Am J Hematol

Costa BA, Costa TA, Pak K, Patel A, Felix N, Mouhieddine TH, Richter J

doi: 10.1002/ajh.27314

ESMO 2024

Lymphoma

Tisa-cel demonstrates high efficacy and manageable safety profile in patients with R/R follicular lymphoma

Further Publications

Maternal and obstetric outcomes in women with pregnancy-associated haematological malignancies: an observational nationwide cohort study

Lancet Haematol

Pinson P, Boussaid I, Decroocq J, Chouchana L, Birsen G, Barrois M, Tsatsaris V, Godeberge C, Zerbit J, Burroni B, Pene F, Huynh L, Charlier C, Tamburini J, Beeker N, Collier M, Bouscary D, Treluyer JM, Birsen R

doi: 10.1016/S2352-3026(24)00288-6

Lung, Respiratory and Thoracic Cancer

Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53

Lung Cancer

Wu M, Zhou N, Guan M, Wang Y, Wang Y

doi: 10.1016/j.lungcan.2024.108068

EHA 2024

Myelodysplastic syndromes

Related content

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment

The IASLC Pleural Mesothelioma Staging Project: Proposal for Revision of the TNM Stage Groupings in the Forthcoming (Ninth) Edition of the TNM Classification for Pleural Mesothelioma

Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trial

Treatment of Pleural Mesothelioma: ASCO Guideline Update

Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed multiple myeloma: A systematic review and meta-analysis

Tisa-cel demonstrates high efficacy and manageable safety profile in patients with R/R follicular lymphoma

Maternal and obstetric outcomes in women with pregnancy-associated haematological malignancies: an observational nationwide cohort study

Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53

EVl-2: Vitamin C supplementation shows promising results in early-stage myeloid malignancies and precursor conditions